SCHEMBL3593036

SCHEMBL3593036

COC(=O)c1cc(C(F)(F)F)cc(S(=O)(=O)Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.60
CNR1 P21554 1/20 0.49
CES2 O00748 1/20 0.42
CFTR P13569 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
GPR35 Q9HC97 1/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 2/20 0.40
POLB P06746 2/20 0.40
GAA P10253 1/20 0.40
NFKB1 P19838 1/20 0.40
XDH P47989 1/20 0.40
GFER P55789 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12097450 0.86 NOTUM (0.62) NOTUMCNR1CES2CFTRCA12
SCHEMBL2324813 0.85 CA12 (0.50) NOTUMCA12CA1CA2CA7
SCHEMBL4599408 0.85 CA12 (0.50) NOTUMCA12CA1CA2CA7
SCHEMBL29659866 0.84 NOTUM (0.60) NOTUMCNR1CES2CFTRCA12
SCHEMBL21609843 0.84 NOTUM (0.60) NOTUMCNR1CES2CFTRCA12
SCHEMBL8051192 0.83 NOTUM (0.59) NOTUMCNR1CES2CFTRCA12
SCHEMBL475762 0.83 NOTUM (0.77) NOTUMCNR1CES2CFTRCA12
SCHEMBL1999038 0.83 NOTUM (0.77) NOTUMCNR1CES2CFTRCA12
SCHEMBL3601186 0.82 NOTUM (0.57) NOTUMCNR1CES2CFTRCA12
SCHEMBL21609873 0.82 NOTUM (0.57) NOTUMCNR1CES2CFTRCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10385022-B2 3-amino-pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2019-08-20 US disclosed
EP-2834226-B1 1,2-PYRIDAZINE, 1,6-PYRIDAZINE OR PYRIMIDINE-BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS HOFFMANN LA ROCHE (CH) 2016-05-25 EP disclosed
CN-103415507-B As the 3-amino-pyridine class of GPBAR1 agonist HOFFMAN-LA ROCHE LTD. (CH) 2016-03-02 CN disclosed
US-20150152058-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN-LA ROCHE INC. 2015-06-04 US disclosed
EP-2681194-B1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN LA ROCHE (CH) 2015-04-15 EP disclosed
US-8987307-B2 3-amino-pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2015-03-24 US disclosed
EP-2834226-A1 1,2- PYRIDAZINE, 1,6- PYRIDAZINE OR PYRIMIDINE - BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS F. Hoffmann-La Roche AG (CH) 2015-02-11 EP disclosed
CN-104203935-A 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as GPBAR1 modulators HOFFMANN LA ROCHE 2014-12-10 CN disclosed
US-8748434-B2 1,2-pyridazines, 1,6-pyridazines and pyrimidines ROCHE PALO ALTO LLC (US) 2014-06-10 US disclosed
EP-2681194-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2014-01-08 EP disclosed
CN-103415507-A 3-amino-pyridines as GPBAR1 agonists HOFFMANN LA ROCHE 2013-11-27 CN disclosed
US-20130267519-A1 1,2-PYRIDAZINES, 1,6-PYRIDAZINES AND PYRIMIDINES HOFFMANN-LA ROCHE INC. (US) 2013-10-10 US disclosed
WO-2013149977-A1 1,2- PYRIDAZINE, 1,6- PYRIDAZINE OR PYRIMIDINE - BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-10-10 WO disclosed
US-20120232051-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN-LA ROCHE INC. 2012-09-13 US disclosed
WO-2012117000-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-07 WO disclosed
US-20100087432-A1 PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY NOVARTIS AG (CH) 2010-04-08 US disclosed
EP-1828172-B1 PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY NOVARTIS AG (CH) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385022-B2 3-amino-pyridines as GPBAR1 agonists GPBAR1, ADRA1B, GPR119 NOTUM 4641/4885CNR1 38/4885CES2 3332/4885
US-20120232051-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS GPBAR1, ADRA1B, GPR119 NOTUM 4641/4885CNR1 38/4885CES2 3332/4885
US-20100087432-A1 PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY PRLHR, AVPR2, CRHR2 NOTUM 2466/4885CNR1 77/4885CES2 3374/4885
US-20150152058-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS GPBAR1, ADRA1B, GPR119 NOTUM 4641/4885CNR1 38/4885CES2 3332/4885
US-20130267519-A1 1,2-PYRIDAZINES, 1,6-PYRIDAZINES AND PYRIMIDINES GPBAR1, P2RY1, P2RY2 NOTUM 4681/4885CNR1 44/4885CES2 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.